Aspirina para prevenção cardiovascular primária em pacientes com diabetes: incertezas e oportunidades.

Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities – Thrombosis and Haemostasis

Diretriz relacionada: USPSTF draft statement revises previous guidance and now recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults aged 60 years or older.

Estudos randomizados relacionados:

Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease

Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes

Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

Metanálises relacionadas:

Meta-Analysis: Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events

Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups – BMC Medicine

Opiniões relacionadas:

Aspirin for Primary Prevention: Is This the End of the Road?

Evidence evolving on aspirin as prevention – ACP Internist